All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 4, 2023
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Chess board and hybrid pawn

Deals and M&As remain level through April; more than a third for COVID-19

May 22, 2020
By Karen Carey
No Comments
Of the 160 biopharma deals tracked by BioWorld during the month of April, 36% are for collaborations focusing on the development of therapeutics and vaccines for COVID-19.
Read More

Med-tech gainers and losers for May 18-22, 2020

May 22, 2020
No Comments
The top 10 med-tech stock gainers and losers for the week.
Read More

Biopharma money raised: Jan. 1-May 21, 2020

May 22, 2020
No Comments
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More

Money raised by biopharma: 2020 vs. 2019

May 22, 2020
No Comments
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biggest gainers and losers for the week of May 18-22, 2020

May 22, 2020
No Comments
The top 10 biopharma stock gainers and losers for the week.
Read More
R&D money

Biopharmas continue to ramp up their R&D spending, analysis finds

May 19, 2020
By Peter Winter
No Comments
According to an analysis conducted by BioWorld of the first quarter 2020 financial reports filed by the top 100 public biopharmaceutical companies ranked by market cap, and excluding big pharma companies, the amount that was invested in research and development (R&D) during the period increased by 13% compared to the same period last year.
Read More
Doctor and patient consultation

Clinical trials still lack diversity, FDA encouraging inclusiveness

May 18, 2020
By Brian Orelli
No Comments
Women, black and Hispanic/Latinx participants were underrepresented in pivotal clinical trials for drugs approved from 2007 to 2017, according to a new report by the Tufts Center for the Study of Drug Development. In the pivotal clinical trials, 44.9% of patients were women. Participants who identified as black or of African descent were the most underrepresented participant group, representing 5.4% of participants in clinical trials.
Read More

Week in review for May 11-15, 2020: Drug developers come roaring back in April

May 18, 2020
By Peter Winter
No Comments
A quick look back at top stories.
Read More
Biopharma research illustration
Regulatory data

April brings five NME approvals, 11 fast tracks; 25% focused on COVID-19

May 15, 2020
By Karen Carey
No Comments
While a significant number of clinical trial delays occurred during the month of April, it was business as usual from a regulatory standpoint for companies with late-stage therapies ready for the market and for those targeting underserved patient populations.
Read More

Biopharma money raised: Jan. 1-May 14, 2020

May 15, 2020
No Comments
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Previous 1 2 … 112 113 114 115 116 117 118 119 120 … 153 154 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 3, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Feb. 3, 2022.
  • Setpoint Medical - vagus nerve stimulation device

    Setpoint Medical lands up to $145M to advance RA implant

    BioWorld MedTech
    Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...
  • CFIUS singles out mergers with Chinese companies as potential national security threats

    BioWorld
    Proposed mergers with Chinese companies will likely be subject to increased scrutiny from the Committee on Foreign Investment in the United States (CFIUS) as...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing